Table 1.
Study | Year | Country | Publication type | RCTa type | Sample size | Age, mean | Sex (male; %) | Health condition | Setting |
Valdes et al [46] | 2012 | United States | Journal article | Parallel | 195 | 77.7 | 33.3 | MCIb | Clinical |
Zhuang et al [47] | 2013 | China | Journal article | Parallel | 33 | 83.1 | 24.2 | MCI; dementia | Clinical |
Hagovská et al [48] | 2016 | Slovakia | Journal article | Parallel | 80 | 67 | 51.2 | MCI | Clinical |
Singh et al [49] | 2014 | Australia | Journal article | Factorial | 100 | 70.1 | 32 | MCI | Community |
Gooding et al [50] | 2016 | United States | Journal article | Parallel | 96 | 75.6 | 58.1 | MCI | Clinical |
Liao et al [51] | 2021 | Taiwan | Journal article | Parallel | 61 | 81.5 | 32.6 | MCI | Community |
Finn and McDonald [52] | 2015 | Australia | Journal article | Parallel | 31 | 75.6 | 71 | MCI | Clinical |
Park and Park [53] | 2017 | South Korea | Journal article | Parallel | 78 | 67.3 | 53.8 | MCI | Community |
Cavallo et al [54] | 2016 | Italy | Journal article | Parallel | 80 | 76.4 | 36.3 | ADc | Clinical |
Leung et al [55] | 2015 | Hong Kong | Journal article | Parallel | 209 | 70.1 | 21.5 | MCI | Community |
Yang and Kwak [56] | 2017 | South Korea | Journal article | Parallel | 20 | 71 | 70 | AD | Clinical |
Tarnanas et al [57] | 2014 | Greece | Book chapter | Parallel | 114 | 70.3 | 39 | MCI | Clinical |
Flak et al [58] | 2019 | Norway | Journal article | Parallel | 85 | 66 | 66.7 | MCI | Clinical |
Herrera et al [59] | 2012 | France | Journal article | Parallel | 22 | 76.6 | 50 | MCI | Clinical |
Savulich et al [60] | 2017 | United Kingdom | Journal article | Parallel | 42 | 76.1 | 59.5 | MCI | Clinical |
Boller et al [61] | 2012 | France | Journal article | Parallel | 36 | 81.2 | 36.1 | AD | Clinical |
Karssemeijer et al [62] | 2019 | Netherlands | Journal article | Parallel | 115 | 79.9 | 53.9 | Dementia | Clinical, community |
Hyer et al [63] | 2015 | United States | Journal article | Parallel | 68 | 75.2 | 47.1 | MCI | Community |
aRCT: randomized controlled trial.
bMCI: mild cognitive impairment.
cAD: Alzheimer disease.